Literature DB >> 11257010

Xenograft model for identifying chemotherapeutic agents against papillomaviruses.

A Pawellek1, G Hewlett, J Kreuter, H Rübsamen-Waigmann, O Weber.   

Abstract

The report describes the establishment and characterization of a mouse xenograft transplantation model for the study of papillomavirus infection of bovine skin. Calf scrotal skin was inoculated with bovine papillomavirus type 2 before grafting it to the dorsum of severe combined immunodeficient mice. The grafted skin contained epidermis, dermis, and a thin layer of fat. After 5 months the induced warts not only showed histological features of papillomavirus infections but also tested positive for viral DNA and papillomavirus capsid antigen. The formation of infectious virions was demonstrated by inoculation of new transplants with crude extract from the induced warts as well as in a cell culture focus assay. Topical application of bromovinyl-2'-deoxyuridine led to a reduction in viral DNA content in the developing wart. This small-animal xenograft model should be useful for characterizing antiviral compounds and providing an understanding of the regulation of papillomavirus infections.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257010      PMCID: PMC90419          DOI: 10.1128/AAC.45.4.1014-1021.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  [(E)-5-(2-bromovinyl)-2'-desoxyuridine--a new nucleoside analog with selective inhibitory action against herpesviruses. Studies in cell culture and animal experiments].

Authors:  J Reefschläger; P Wutzler; K D Thiel; H Töpke; D Bärwolff; P Langen
Journal:  Pharmazie       Date:  1987-06       Impact factor: 1.267

Review 2.  Molecular targets for human papillomaviruses: prospects for antiviral therapy.

Authors:  W C Phelps; J A Barnes; D C Lobe
Journal:  Antivir Chem Chemother       Date:  1998-09

3.  Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8+ cells and persistence of viral DNA after regression.

Authors:  R Selvakumar; A Schmitt; T Iftner; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  A quantitative in vitro focus assay for bovine papilloma virus.

Authors:  I Dvoretzky; R Shober; S K Chattopadhyay; D R Lowy
Journal:  Virology       Date:  1980-06       Impact factor: 3.616

Review 5.  New concepts on the role of human papillomavirus in cell cycle regulation.

Authors:  S M Syrjänen; K J Syrjänen
Journal:  Ann Med       Date:  1999-06       Impact factor: 4.709

6.  Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines.

Authors:  G Andrei; R Snoeck; J Piette; P Delvenne; E De Clercq
Journal:  Oncol Res       Date:  1998       Impact factor: 5.574

7.  In vivo transformation of human skin with human papillomavirus type 11 from condylomata acuminata.

Authors:  J W Kreider; M K Howett; N L Lill; G L Bartlett; R J Zaino; T V Sedlacek; R Mortel
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

8.  Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types.

Authors:  W F Jarrett; B W O'Neil; J M Gaukroger; K T Smith; H M Laird; M S Campo
Journal:  Vet Rec       Date:  1990-05-12       Impact factor: 2.695

9.  Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4.

Authors:  L M Chandrachud; G J Grindlay; G M McGarvie; B W O'Neil; E R Wagner; W F Jarrett; M S Campo
Journal:  Virology       Date:  1995-08-01       Impact factor: 3.616

10.  Ribavirin mitigates wart growth in rabbits at early stages of infection with cottontail rabbit papillomavirus.

Authors:  R S Ostrow; K M Forslund; R C McGlennen; D P Shaw; P M Schlievert; M A Ussery; J W Huggins; A J Faras
Journal:  Antiviral Res       Date:  1992-02       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.